Waldenstrom Macroglobulinemia

News

ASCT is a Feasible Treatment Option for Patients With WM

12/22/2021

Data from a real-world analysis on the role of ASCT in patients with WM was presented at the 2021 ASH Annual Meeting to review response outcomes, survival outcomes, and relapsed risk factors in patients with WM who underwent ASCT.

Data from a real-world analysis...

12/22/2021

Oncology

Test Your Knowledge

Quiz: Is This Triplet Combo Effective for R/R WM?

11/17/2021

True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.

True or false: When used a...

11/17/2021

Oncology

News

Triplet Therapy Found Effective, Well-Tolerated in R/R WM

11/17/2021

A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.

A phase 2 trial found that...

11/17/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment Shows Continued Efficacy in TN and R/R WM?

11/10/2021

Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?

Which treatment demonstrated...

11/10/2021

Oncology

News

Tirabrutinib Shows Continued Efficacy in TN, R/R WM

11/10/2021

A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.

A report on 2 years of follow-up...

11/10/2021

Oncology

Videos

New Approaches to Treating Waldenström Macroglobulinemia

11/04/2019

Steven Treon, MD, PhD, FACP, FRCP, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.

Steven Treon, MD, PhD, FACP,...

11/04/2019

Oncology

Venetoclax Well-Tolerated in Previously Treated Waldenström Macroglobulinemia

12/18/2018

Patients with symptomatic, previously treated WM responded well to therapy with venetoclax, according results from a recent phase 2 clinical trial.

Patients with symptomatic,...

12/18/2018

Oncology

Ibrutinib–Rituximab Combo Effective, Safe for Waldenström Macroglobulinemia

12/12/2018

The combination of ibrutinib and rituximab consistently outshined rituximab alone in the treatment of patients with WM, according to follow-up results from the iNNOVATE trial.

The combination of ibrutinib and...

12/12/2018

Oncology